Platinum Today, in its August 31, 2012 article, reports that newly developed cancer drug is based on platinum group metal ingredient.
Extract :
|
|
|
|
|
|
A new cancer drug based on platinum group metal
ruthenium has been developed and tested by researchers at the University of
Vienna.
The
drug, called NKP-1339, is inserted directly into the tumour
cell, where it is activated and begins the process of destroying it.
This is
the first cancer drug based on ruthenium, whose active ingredients
transferrin and albumin are inserted into the tumour.
Phase
one of the clinical trials has already been completed on patients with
metastatic solid tumours, with early results
indicating anti-cancer activity.
Participants,
who were selected because they had stopped responding to standard treatments
for cancer administered in the past, also tolerated the drug well.
Researchers
said the findings confirmed what had emerged from pre-clinical studies and a
phase II clinical trial for the drug is due to take place in the future.
Sources
|
|
